ClinicalTrials.Veeva

Menu

A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Thalamotomy for the Treatment of Medication-Refractory Tremor Dominant Idiopathic Parkinson's Disease

InSightec logo

InSightec

Status

Enrolling

Conditions

Tremor Associated With Tremor Dominant Parkinson's Disease

Treatments

Device: Unilateral thalamotomy

Study type

Observational

Funder types

Industry

Identifiers

Details and patient eligibility

About

The objectives of this study are to collect the long-term safety and effectiveness data of performing thalamotomy for tremor dominant Parkinson's Disease (TDPD) using the Exablate Neuro system.

Full description

This is a post-approval registry which is required by of the approval under PMA P150038/S006 for the Exablate® Model 4000 (Exablate Neuro) Type 1.0 and Type 1.1 for unilateral thalamotomy in the treatment of medication refractory Tremor Dominant Parkinson's Disease (TDPD). Subjects participating in this registry will have received a unilateral thalamotomy (ventralis medius) prior to enrollment using the commercially available Exablate Neuro for the treatment of Essential tremor and TDPD.

The following assessments will be collected at Baseline,1, 3, 6, and 12 months post Exablate procedure and annually thereafter for 5 years:

  • Adverse Events (AEs) (does not apply to Baseline Visit)
  • Medication usage
  • Clinical Rating Scale for Tremor (CRST) ON medication
  • Unified Parkinson's Disease Rating Scale Part III ON medication
  • EQ-5D-5L
  • WPAI-GH

Enrollment

50 estimated patients

Sex

All

Ages

30 to 99 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Men and women, age 30 years and older
  2. Subject undergoing an Exablate procedure for their planned TDPD treatment; per local institution standard of care.
  3. Subject is willing to cooperate with the Registry requirements including compliance with the regimen and completion of all study visits
  4. Subject has signed and received a copy of the approved informed consent form

Exclusion criteria

Subject does not agree to participate or is unlikely to participate for the entirety of the study.

Trial design

50 participants in 1 patient group

Post Exablate Neuro Thalamotomy for Tremor Associated with Tremor Dominant Parkinson's Disease
Description:
This is a post Exablate Neuro Thalamotomy registry. No intervention is performed under this registry protocol.
Treatment:
Device: Unilateral thalamotomy

Trial contacts and locations

2

Loading...

Central trial contact

Mark Grassman, Ph.D.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems